6α-fluoro-17α,21-dihydroxy-16β-methyl-pregna-4,9(11)-diene-3,20-dione | 105384-40-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 6α-fluoro-17α,21-dihydroxy-16β-methyl-pregna-4,9(11)-diene-3,20-dione
• 英文别名: 6α-fluoro-17,21-dihydroxy-16β-methyl-pregna-4,9(11)-diene-3,20-dione；6α-fluoro-16β-methyl-17α,21-dihydroxypregna-4,9(11)-diene-3,20-dione；6alpha-Fluoro-17,21-dihydroxy-16beta-methyl-pregna-4,9(11)-diene-3,20-dione；(6S,8S,10R,13S,14S,16S,17R)-6-fluoro-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-2,6,7,8,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one
• CAS: 105384-40-5
• 化学式: C₂₂H₂₉FO₄
• 分子量: 376.468
• InChiKey: MUEOUHRWNRABSW-LCMQHTLGSA-N

物化性质

• 沸点：
  544.6±50.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• CRYSTALLINE FORMS OF C21H22Cl2N4O2
  申请人：BIOMED VALLEY DISCOVERIES, INC.

  公开号：US20170320851A1

  公开（公告）日：2017-11-09

  The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.

  本发明提供了公式（I）化合物的晶体形式。还提供包含所提供晶体形式的药物组合物以及使用所提供的晶体形式和药物组合物治疗癌症的方法。
• CRYSTALLINE C21H22Cl2N4O2 MALONATE
  申请人：BIOMED VALLEY DISCOVERIES, INC.

  公开号：US20160221988A1

  公开（公告）日：2016-08-04

  The present invention provides a malonate salt of a compound of formula (I): which is a crystalline salt. Also provided are pharmaceutical compositions that include the provided malonate salt and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.

  本发明提供了公式（I）化合物的马隆酸盐，该盐为晶体盐。还提供了包含所提供的马隆酸盐的药物组合物以及使用所提供的晶体形式和药物组合物治疗癌症的方法。
• Novel heparin derivatives, a process for their preparation and their use in pharmaceuticals
  申请人：Kabi Pharmacia AB

  公开号：EP0302034A1

  公开（公告）日：1989-02-01

  A novel complex of (a) a metal ion selected from copper, calcium, manganese, iron, and zinc ions, and (b) a fraction of heparin, heparan sulfate, low molecular weight heparin, low molecular weight heparan sulfate, heparin fragments, heparan sulfate fragments, and oligosaccharides derived from heparin or from heparan sulfate, or a salt of such fractions which fractions bind to the said metal ion, said complex containing from 5 to 1,000 nmole metal of component (a) per µmole of component (b).

  一种新型的 (a) 选自铜、钙、锰、铁和锌离子的金属离子、 和 (b) 部分肝素、硫酸肝素、低分子量肝素、低分子量硫酸肝素、肝素片段、硫酸肝素片段、肝素或硫酸肝素衍生的低聚糖，或这些部分的盐，这些部分与所述金属离子结合、 所述复合物每微摩尔组分（b）含有 5 至 1,000 毫微摩尔组分（a）的金属。
• Cationic lipid compositions targeting angiogenic endothelial cells
  申请人：The Regents of the University of California

  公开号：EP1767192A2

  公开（公告）日：2007-03-28

  Angiogenic endothelial cells are selectively targeted with lipid/DNA complexes or cationic liposomes containing a substance which affects the targeted cells by inhibiting or promoting their growth. A site of angiogenesis can be precisely located by administering cationic liposomes containing a detectable label. The complexes may comprise nucleotide constructs which are comprised of promoters which are selectively and exclusively activated in the environment of an angiogenic endothelial cell.

  用脂质/DNA 复合物或含有某种物质的阳离子脂质体选择性地靶向血管生成内皮细胞，通过抑制或促进其生长来影响靶细胞。通过施用含有可检测标记的阳离子脂质体，可精确定位血管生成部位。复合物可包含核苷酸结构体，这些核苷酸结构体由启动子组成，启动子在血管生成内皮细胞的环境中被选择性地专门激活。
• Crystalline forms of C21H22Cl2N4O2
  申请人：BIOMED VALLEY DISCOVERIES, INC.

  公开号：US10183927B2

  公开（公告）日：2019-01-22

  The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.

  本发明提供了式 (I) 化合物的结晶形式： 还提供了包括所提供晶体形式的药物组合物，以及使用所提供晶体形式和药物组合物治疗癌症的方法。